Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia

Completed · Phase 3 · Has a placebo group

Conditions studied: Cervical Dysplasia

In brief

To determine if the use of oral Diindolylmethante (DIM), a marketed cruciferous vegetable based dietary supplement (Bioresponse-DIM), is associated with the regression of cervical dysplasia in otherwise healthy women.

Key facts

Study ID

NCT00212381

Run by

New York Presbyterian Hospital

People needed

62

Starts

2000-09-01

Expected to finish

2010-07-01

Last updated by the study team

2017-03-29

Who can join

Age: 18 and older, up to 80. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Non pregnant women greater than or equal to 18 years of age able to consent
• CIN II or III confirmed by histology
• Karnofsky performance status >= 80
• No prior treatment for dysplasia in the past 4 months

You may not qualify if…

• Incompletely visible lesion
• Diethylstilbestrol (DES) exposure
• HIV seropositive

Where it is running

• NYU School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.